Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

Zhixin TU; Yan WANG; Jianjie HUANG; Qinglong JIN

doi:10.3969/j.issn.1001-5256.2023.04.010

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 804-809

PDF( 4219 KB)

Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.04.010

Department of Hepatology, The First Hospital of Jilin University, Changchun 130000, China

Research funding:

National Natural Science Foundation of China (81270484)

More Information

Corresponding author: JIN Qinglong, jinql@jlu.edu.cn(ORCID: 0000-0002-4626-9828)
Received Date: 2022-09-07
Accepted Date: 2022-10-24
Published Date: 2023-04-20

Abstract

Abstract

Objective To investigate the effect of Compound Lingdan Capsule on serum biochemical parameters and liver fibrosis degree in a mouse model of liver fibrosis. Methods A total of 125 specific pathogen-free male C57BL/6 mice were randomly divided into normal control group with 5 mice, CCl₄ model group with 15 mice, low-, middle-, and high-dose CCl₄ groups (0.8, 1.6, and 3.2 mg·g^-1·d^-1) with 15 mice in each group, DDC model group with 15 mice, and low-, middle-, and high-dose DDC groups (0.8, 1.6, and 3.2 mg·g^-1·d^-1) with 15 mice in each group. After successful modeling, the mice in the administration groups were given Compound Lingdan Capsule suspension at the respective doses by gavage, and those in the normal control group and the model group were given an equal volume of normal saline by gavage, for 4 consecutive weeks. Blood samples were collected from the eyeballs, and serum was used to measure aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, and bilirubin. Liver tissue samples were collected at the same site of the right lobe of the liver for pathological observation, Sirius Red staining, α-SMA antibody staining, and COL1A1 antibody staining. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Bonferroni method was used for further comparison between two groups. Results Compared with the model group, each dose group had significant reductions in the serum level of ALT and a significant increase in the serum level of albumin after the administration of Compound Lingdan Capsule (all P < 0.05), the levels of AST and bilirubin in the middle and high dose groups were lower (all P < 0.05), and the difference of each index in the high dose group was more significant than that in the low dose group (all P < 0.05). Each dose group had varying degrees of improvement in the pathological changes of the liver and a significant reduction in the number of Sirius Red staining-positive cells, as well as varying degrees of reduction in the protein expression of α-SMA and COL1A1. Conclusion Compound Lingdan Capsule can improve liver function and reduce liver fibrosis degree in mice with liver fibrosis.
- Liver Cirrhosis,
- Mice, Inbred C57BL,
- Compound Lingdan Capsule

FullText(HTML)

References(17)

References

[1]	FRIEDMAN SL. Liver fibrosis-from bench to bedside[J]. J Hepatol, 2003, 38(Suppl 1): S38-S53. DOI: 10.1016/s0168-8278(02)00429-4.
[2]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
[3]	WEISKIRCHEN R, WEISKIRCHEN S, TACKE F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts[J]. F1000Res, 2018, 7: F1000 Faculty Rev-921. DOI: 10.12688/f1000research.14841.1.
[4]	DU WT, REN WL, HU DD, et al. Research progress on reversible animal model of liver fibrosis[J/CD]. Chin J Liver Dis (Electronic Version), 2022, 14(3): 18-21. DOI: 10.3969/j.issn.1674-7380.2022.03.005. 杜文涛, 任万雷, 胡豆豆, 等. 肝纤维化可逆转动物模型研究进展[J/CD]. 中国肝脏病杂志(电子版), 2022, 14(3): 18-21. DOI: 10.3969/j.issn.1674-7380.2022.03.005.
[5]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis (2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[6]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[7]	PAROLA M, PINZANI M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55. DOI: 10.1016/j.mam.2018.09.002.
[8]	LAI M, AFDHAL NH. Liver fibrosis determination[J]. Gastroenterol Clin North Am, 2019, 48(2): 281-289. DOI: 10.1016/j.gtc.2019.02.002.
[9]	HAMMEL P, COUVELARD A, O'TOOLE D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct[J]. N Engl J Med, 2001, 344(6): 418-423. DOI: 10.1056/NEJM200102083440604.
[10]	ARTHUR MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C[J]. Gastroenterology, 2002, 122(5): 1525-1528. DOI: 10.1053/gast.2002.33367.
[11]	KWEON YO, GOODMAN ZD, DIENSTAG JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B[J]. J Hepatol, 2001, 35(6): 749-755. DOI: 10.1016/s0168-8278(01)00218-5.
[12]	DIXON JB, BHATHAL PS, HUGHES NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss[J]. Hepatology, 2004, 39(6): 1647-1654. DOI: 10.1002/hep.20251.
[13]	CZAJA AJ, CARPENTER HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis[J]. J Hepatol, 2004, 40(4): 646-652. DOI: 10.1016/j.jhep.2004.01.009.
[14]	ZHANG Y, LYU WL. Visual analysis of traditional Chinese medicine in the treatment of hepatic fibrosis based on CiteSpace[J]. China Med Herald, 2022, 19(19): 129-132, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202219026.htm 张亚, 吕文良. 基于CiteSpace中医药治疗肝纤维化的可视化分析[J]. 中国医药导报, 2022, 19(19): 129-132, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202219026.htm
[15]	WANG HY, NIU JQ, ZHANG WY, et al. Experimental study on the anti-hepatic fibrosis effect of Compound Lingdan Capsule[J]. Chin Traditional Patent Med, 2014, 36(1): 168-171. DOI: 10.3969/j.issn.1001-1528.2014.01.042. 王化宇, 牛俊奇, 张炜煜, 等. 复方灵丹胶囊抗肝纤维化作用的实验研究[J]. 中成药, 2014, 36(1): 168-171. DOI: 10.3969/j.issn.1001-1528.2014.01.042.
[16]	FALLOWFIELD JA, MIZUNO M, KENDALL TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis[J]. J Immunol, 2007, 178(8): 5288-5295. DOI: 10.4049/jimmunol.178.8.5288.
[17]	DOOLEY S, DELVOUX B, STRECKERT M, et al. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells[J]. FEBS Lett, 2001, 502(1-2): 4-10. DOI: 10.1016/s0014-5793(01)02656-4.

Relative Articles

[1]	Wenhui WANG, Xuhua DUAN, Hao LI, Shuguang JU, Manzhou WANG, Jianzhuang REN, Xinwei HAN. A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2125-2129. doi: 10.3969/j.issn.1001-5256.2021.09.024
[2]	Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
[3]	Ha FuShuang, Han Tao, Liang Ning, Nie XinHua, Zhu ZhengYan. Effect of recombinant human granulocyte colony-stimulating factor on rats with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1565-1569. doi: 10.3969/j.issn.1001-5256.2019.07.028
[4]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[5]	Zhang YongChao, Bi YanZhen, Fang Xiao, Wang QuanYi, Wang QuanQuan, Tang HuiXin, Kong LingBin, Chen Yu, Duan ZhongPing, Shu ZhenFeng, Hong Feng. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
[6]	Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
[7]	Zhou QiFeng, Zhang LingQiang, Liao MengJiao, Pang MingQuan, Li MengXuan, Ren Li, Fan HaiNing. Establishment of a subcutaneous xenograft tumor model of alveolar echinococcosis in nude mice[J]. Journal of Clinical Hepatology, 2018, 34(3): 588-590. doi: 10.3969/j.issn.1001-5256.2018.03.028
[8]	Ji JunSong, Chen Ting, Wang Hui, Wang ChenYi, Zhu XinYing, Yin Hao, Fu ZhiRen. Effect of arsenic trioxide chemotherapy on survival time in liver cancer patients undergoing liver transplantation[J]. Journal of Clinical Hepatology, 2017, 33(9): 1745-1748. doi: 10.3969/j.issn.1001-5256.2017.09.023
[9]	Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025
[10]	Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019
[11]	Pang GuoJin, Chen ShuangJun, Zhao WeiHua, Liu TianHui, Wang Ping, You Hong, Cong Min. Dynamic change of hepcidin in liver fibrosis induced by CCl4 among mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 418-423. doi: 10.3969/j.issn.1001-5256.2015.03.025
[12]	Gao ChengGuang, Chen RiXia. Clinical research on treatment of advanced primary liver cancer with combination of thymosin α1 and arsenic trioxide[J]. Journal of Clinical Hepatology, 2015, 31(4): 564-568. doi: 10.3969/j.issn.1001-5256.2015.04.021
[13]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
[14]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[15]	Jiang Han, Wang XueFeng, Wang ZiHao, Xu Bin, Shi WeiBin. The establishment of rabbit VX2 hepatic tumor model and the application of nano-scale microbubble contrast agent in the diagnosis of this model[J]. Journal of Clinical Hepatology, 2011, 27(7): 746-748.
[16]	Sun LinLin, Shi Jun, Hao JingHua, Ren WanHua, Yan ChunYing, Zhang Jie, Lin XiaoYan, Cui Bin. Effect of high-fat diet on establishment of a rat non-alcoholic steatohepatitis/liver fibrosis model[J]. Journal of Clinical Hepatology, 2011, 27(3): 254-257+272.
[17]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.
[18]	Song Yu, Yu Zheng, Fan YanHua, Yao ShuKun, Wang TaiLing. A rat model of hepatic veno-occlusive disease induced by the Gynura root water decoction[J]. Journal of Clinical Hepatology, 2011, 27(8): 860-864.
[19]	Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	杨晓曼. γ-谷氨酰转移酶/血小板在乙肝肝硬化失代偿期患者中的表达及临床意义. 河南医学研究. 2024(08): 1407-1410 .
2.	刘爱华，符建，陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究. 实用肝脏病杂志. 2023(05): 634-637 .
3.	肖少伟，杜亚哲. γ-谷氨酰转移酶/胆碱酯酶比值与γ-谷氨酰转移酶/血小板比值对慢性乙型肝炎患者肝纤维化程度的预测效能. 实用医技杂志. 2023(11): 812-815 .
4.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
5.	桑阿利. APRI、Fib-4和Fibroscan联合诊断慢性乙型肝炎肝纤维化程度的价值. 甘肃医药. 2022(10): 896-898 .
6.	王晔恺，于倩，姚燕珍，罗雯斌，洪开听，鲍舟君. 对数几率回归模型构建联合预测因子对慢性乙型肝炎患者早期肝硬化诊断的临床应用. 中国卫生检验杂志. 2021(01): 90-93+97 .
7.	陈兴，梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 .
8.	黄腊平，陈焰. 基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析. 清远职业技术学院学报. 2020(02): 35-38 .
9.	栗红江，何久胜，胡素玲，何福亮，田彦卿，刘震霞. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能. 临床军医杂志. 2020(09): 1090-1091+1094 .
10.	熊静，林登娜，翁伟镇，陈俊峰，曹会娟，张绍全，张静，高隽，林炳亮. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化. 国际病毒学杂志. 2020(05): 403-406 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (470) PDF downloads(48)

Effect of Compound Lingdan Capsule on liver function and fibrosis degree in mice with liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.04.010